Varenicline Tartrate
Varenicline Tartrate structure
|
Common Name | Varenicline Tartrate | ||
|---|---|---|---|---|
| CAS Number | 375815-87-5 | Molecular Weight | 361.35 | |
| Density | N/A | Boiling Point | 400.6ºC at 760 mmHg | |
| Molecular Formula | C17H19N3O6 | Melting Point | 206-208ºC | |
| MSDS | Chinese USA | Flash Point | 48.2 °F | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
|
Concurrent access to nicotine and sucrose in rats.
Psychopharmacol. Ser. 232(8) , 1451-60, (2015) Animal models that allow concurrent access to drug and nondrug reinforcers provide unique insight into the etiology, maintenance, and treatment of drug use.We sought to develop and utilize a concurrent access procedure with nicotine and sucrose in rats.Pressi... |
|
|
Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.
Neuropharmacology 99 , 142-55, (2015) Chronic treatment with nicotine is known to increase the α4β2-nAChR sites in brain, to decrease α6β2-nAChR sites and to have minimal effect on α3β4-and α7-nAChR populations. Varenicline is now used as a smoking cessation treatment, with and without continued ... |
|
|
Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization.
Alcohol. Clin. Exp. Res. 38(12) , 3033-42, (2015) Varenicline, a partial nicotinic acetylcholine receptor (nAChR) agonist, is a promising new drug for the treatment of alcohol (ethanol [EtOH]) dependence. Varenicline has been approved by the Food and Drug Administration as a smoking cessation therapeutic and... |
|
|
MiR-153 targets the nuclear factor-1 family and protects against teratogenic effects of ethanol exposure in fetal neural stem cells.
Biol. Open 3(8) , 741-58, (2014) Ethanol exposure during pregnancy is an established cause of birth defects, including neurodevelopmental defects. Most adult neurons are produced during the second trimester-equivalent period. The fetal neural stem cells (NSCs) that generate these neurons are... |
|
|
Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats.
Neuropsychopharmacology 39(8) , 1843-51, (2014) Tobacco dependence is difficult to treat, with the vast majority of those who try to quit relapsing within the first year. Improvements in smoking cessation therapies may be achieved by improving current preclinical research methods. However, most experimenta... |
|
|
Varenicline Interactions at the 5-HT3 Receptor Ligand Binding Site are Revealed by 5-HTBP.
ACS Chem. Neurosci. 6 , 1151-7, (2015) Cys-loop receptors are the site of action of many therapeutic drugs. One of these is the smoking cessation agent varenicline, which has its major therapeutic effects at nicotinic acetylcholine (nACh) receptors but also acts at 5-HT3 receptors. Here, we report... |
|
|
Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments.
Behav. Brain Res. 291 , 342-50, (2015) Studies have demonstrated that administration of the neuronal nicotinic receptor agonist varenicline to rats with olivocerebellar lesions attenuates balance deficits on a rotorod and balance beam, but the effects of this drug on gait deficits have not been in... |
|
|
Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys.
Psychopharmacology 233 , 761-71, (2016) Due to the rising costs of drug development especially in the field of neuropsychiatry, there is increasing interest in efforts to identify new clinical uses for existing approved drugs (i.e., drug repurposing).The purpose of this work was to evaluate in anim... |
|
|
Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial.
Alcohol. Clin. Exp. Res. 39 , 2189-99, (2015) Alcohol dependence is a devastating illness affecting a large population, and new pharmacological treatments with good efficacy are greatly needed. One potential candidate is varenicline, a smoking cessation agent with partial agonist action at α4 β2 nicotini... |
|
|
Varenicline disrupts prepulse inhibition only in high-inhibitory rats.
Prog. Neuropsychopharmacol. Biol. Psychiatry 53 , 54-60, (2014) Varenicline, a widely used smoking cessation drug, has partial agonistic activity at α4β2 nicotinic receptors, and full agonistic activity at α7 nicotinic receptors. Thus it may interact with cognitive processes and may alleviate some of the cognitive disturb... |